首頁 > 市場調查報告書 > 製藥

非專利藥糖尿病生物製劑生技仿製藥

市場調查報告書

商品編碼

1741457

基礎胰島素市場按類型、給藥裝置、適應症、年齡層、分銷管道和地區分類

Basal Insulin Market, By Type, By Delivery Device, By Indication, By Age Group, By Distribution Channel, By Geography

出版日期: 2025年03月27日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

基礎胰島素市場規模預計在 2025 年為 196.5 億美元，預計到 2032 年將達到 378.1 億美元，2025 年至 2032 年的複合年成長率為 9.8%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	196.5億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	9.80%	2032年價值預測	378.1億美元

基礎胰島素是一種長效胰島素，可全天穩定釋放胰島素，以控制糖尿病患者的血糖值。它通常用於需要胰島素治療的第1型或第2型糖尿病患者。基礎胰島素有助於維持兩餐之間和空腹期間的穩定血糖值，為最佳糖尿病管理奠定基礎。

全球基礎胰島素市場正經歷顯著成長，這得益於全球糖尿病盛行率的不斷上升。根據國際糖尿病聯盟的數據，預計到2045年，全球成年糖尿病患者人數將達7億人。糖尿病患者數量的成長刺激了對基礎胰島素的需求，而基礎胰島素是糖尿病管理的重要組成部分。

市場動態：

基礎胰島素市場受多種因素驅動。糖尿病（尤其是第2型糖尿病）盛行率的上升是市場的主要驅動力。久坐不動、不良飲食和肥胖等不健康的生活習慣導致全球糖尿病盛行率上升。因此，預計基礎胰島素的需求將大幅成長。

此外，胰島素治療技術的進步也推動了市場的成長。藥物動力學特性得到改善的胰島素類似物的開發顯著提高了基礎胰島素治療的療效和便利性。這些進步帶來了更好的血糖控制，並降低了低血糖風險。

例如，2023年10月23日，與中國製藥公司通化東寶藥業股份有限公司合作的臨床階段生物製藥公司Adsia宣布，其Chaperone組合THDB0207（包含Insulin Lispro和Insulin Glargine）的三項臨床試驗取得了積極成果。這三項試驗表明，BC組合是一種有效的胰島素，兼具長效和速效胰島素的特性。因此，它可以確保餐後和空腹血糖控制。

然而，基礎胰島素市場的成長仍面臨許多阻礙因素。其中包括胰島素治療成本高、部分地區醫療保健服務有限等。此外，胰島素生產和分銷的嚴格監管要求也給市場參與者帶來了挑戰。

儘管面臨這些挑戰，基礎胰島素市場仍提供了許多成長機會。老年人口的成長以及人們對糖尿病管理重要性的認知不斷提高，預計將推動市場成長。此外，智慧胰島素輸送系統的開發以及數位技術在糖尿病管理中的整合，也為市場參與者提供了新的探索途徑。

本研究的主要特點

本報告對全球基礎胰島素市場進行了詳細分析，包括預測期 2025-2032 的市場規模和年複合成長率(CAGR)，以 2024 年為基準年。
它揭示了不同領域的潛在收益成長機會，並解釋了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
根據公司亮點、產品系列、主要亮點、業績和策略，列出了全球基礎胰島素市場的主要企業。
本報告的見解將使負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
全球基礎胰島素市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球基礎胰島素市場的各種策略矩陣來促進他們的決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 19.65 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	9.80%	2032 Value Projection:	USD 37.81 Bn

Basal insulin is a type of long-acting insulin that provides a steady release of insulin throughout the day and night to control blood sugar levels in individuals with diabetes. It is typically prescribed for individuals with type 1 diabetes or type 2 diabetes who require insulin therapy. Basal insulin helps maintain stable blood sugar levels between meals and during periods of fasting, providing a foundation for optimal diabetes management.

The global basal insulin market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation, the number of adults with diabetes is expected to reach 700 million by 2045. This rise in diabetes cases is fueling the demand for basal insulin, as it is an essential component of diabetes management.

Market Dynamics:

The basal insulin market is driven by several factors. The rising prevalence of diabetes, particularly type 2 diabetes, is a key driver for the market. Unhealthy lifestyle habits, such as sedentary behavior, poor diet, and obesity, are contributing to the increasing incidence of diabetes globally. As a result, the demand for basal insulin is expected to rise significantly.

In addition, advancements in insulin therapy technologies are also driving the market growth. The development of insulin analogs, which have improved pharmacokinetic properties, has significantly enhanced the efficacy and convenience of basal insulin therapy. These advancements have led to better glycemic control and reduced risks of hypoglycemia.

For instance, on October 23, 2023, Adocia, a biopharmaceutical company in the clinical stage, announced that Tonghua Dongbao Pharmaceutical Co. Ltd., a pharmaceutical company based in China, is its partner and has released positive results from three clinical studies conducted on the BioChaperone Combo THDB0207 formulation, which contains insulin lispro and insulin glargine. These three studies showed that BC Combo is a useful insulin that combines the qualities of both long-acting and rapid-acting insulin. As a result, it can guarantee glycemic control during the postprandial and fasting periods.

However, there are certain restraints that may hinder the growth of the basal insulin market. The high cost of insulin therapy and limited access to healthcare in certain regions are some of the barriers. Additionally, the stringent regulatory requirements for insulin production and distribution pose challenges for market players.

Despite these challenges, there are several opportunities for growth in the basal insulin market. The increasing geriatric population, as well as the growing awareness about the importance of diabetes management, are expected to drive the market growth. Furthermore, the development of smart insulin delivery systems and the integration of digital technologies in diabetes management present new avenues for market players to explore.

Key Features of the Study:

This report provides an in-depth analysis of the global basal insulin market including market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, with 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key players in the global basal insulin market are profiled based on company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered in this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Gan & Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories, Merck, Wockhardt, Julphar Diabetes, Medtronic, Beta Bionics, Zealand Pharma, MannKind, Peptron, Dexcom, Senseonics, Medtrum Technologies, SOOIL Development, and Semma Therapeutics
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
The global basal insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal insulin market

Basal Insulin Market Segmentation:

By Type
- Glargine
- Detemir
- Degludec
By Delivery Device
- Syringes
- Pens
- Pumps
- Others (Inhalers, Patches)
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
By Age Group
- Pediatric
- Adults
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- United Laboratories
- Merck
- Wockhardt
- Julphar Diabetes
- Medtronic
- Beta Bionics
- Zealand Pharma
- MannKind
- Peptron
- Dexcom
- Senseonics
- Medtrum Technologies
- SOOIL Development
- Semma Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Basal Insulin Market, By Type
- Global Basal Insulin Market, By Delivery Device
- Global Basal Insulin Market, By Indication
- Global Basal Insulin Market, By Age Group
- Global Basal Insulin Market, By Distribution Channel
- Global Basal Insulin Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of diabetes, particularly type 2 diabetes
- Restraints
High cost of insulin therapy
- Opportunities
Increasing geriatric population
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Basal Insulin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Basal Insulin Market, By Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Glargine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Detemir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Degludec
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Basal Insulin Market, By Delivery Device, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pumps
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Inhalers, Patches)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Basal Insulin Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Basal Insulin Market, By Age Group, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Basal Insulin Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

10. Global Basal Insulin Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

11. Competitive Landscape

Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Gan & Lee Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Tonghua Dongbao Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
United Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Wockhardt
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Julphar Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Medtronic
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Beta Bionics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Zealand Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
MannKind
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Peptron
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Dexcom
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Senseonics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Medtrum Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
SOOIL Development
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Semma Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views